Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination CagriSema vs. Tirzepatide: Which One MELTS Fat Faster? Dr. Dan Obesity Expert